- GSK acquires RAPT Therapeutics for $2.2 billion, with a $1.9 billion upfront investment.
- The acquisition includes ozureprubart, an anti-IgE monoclonal antibody in phase IIb trials.
- Phase IIb trial data for ozureprubart is expected in 2027.
- GSK gains global rights to ozureprubart, excluding mainland China, Macau, Taiwan, and Hong Kong.
Acquisition Details
GSK has completed its acquisition of RAPT Therapeutics, a clinical-stage biopharmaceutical company, for a total cash consideration of approximately $2.2 billion. The upfront investment by GSK, net of cash acquired, is around $1.9 billion. This transaction grants GSK global rights to the ozureprubart program, excluding mainland China, Macau, Taiwan, and Hong Kong.
Ozureprubart Overview
Ozureprubart is a long-acting anti-immunoglobulin E (IgE) monoclonal antibody currently in phase IIb clinical development. It is designed for prophylactic protection against food allergens, targeting IgE, which is responsible for 94% of severe food allergies. The current anti-IgE treatments require frequent injections, posing a burden, especially for children. Ozureprubart offers the potential for dosing every 12 weeks, improving compliance and patient outcomes.
Clinical Development
Data from the phase IIb trial, known as prestIgE, is expected in 2027. The phase III trials will focus on both at-risk adult and pediatric populations. Ozureprubart aims to provide a new option for approximately 25% of patients currently ineligible for existing therapies.
Financial Considerations
In addition to the acquisition cost, GSK will be responsible for success-based milestone and royalty payments to RAPT’s partner, Shanghai Jeyou Pharmaceutical Co., Ltd. This acquisition aligns with GSK's strategy to expand its pipeline in respiratory, immunology, and inflammation areas.
